# Synlogic, Inc.: financial statements, quarterly

SYBX · OTC · CIK 1527599 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/sybx.md) · [Financials](/companies/sybx/financials.md) · [Filings](/companies/sybx/filings.md) · [Insiders](/companies/sybx/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/sybx/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [0.4](/filings/0000950170-24-125567.md) | [2.8 d](/filings/0000950170-25-034820.md) | [0.0](/filings/0000950170-25-067081.md) | [0.0](/filings/0000950170-25-105106.md) | [0.0](/filings/0001193125-25-280270.md) | [0.0 d](/filings/0001193125-26-104262.md) | [0.0](/filings/0001193125-26-224171.md) | [0.0](/filings/0001193125-26-344789.md) | [0.0](/filings/0001193125-25-280270.md) | [0.0 d](/filings/0001193125-26-104262.md) | [0.0](/filings/0001193125-26-224171.md) | [0.0](/filings/0001193125-26-344789.md) |
| Research and development | $m | [9.6](/filings/0000950170-23-061493.md) | [10.1 d](/filings/0000950170-25-034820.md) | [7.7](/filings/0000950170-25-067081.md) | [2.2](/filings/0000950170-24-093282.md) | not reported | not reported | [0.0](/filings/0001193125-26-224171.md) | not reported | not reported | not reported | [0.0](/filings/0001193125-26-224171.md) | not reported |
| Operating income | $m | [(12.6)](/filings/0000950170-24-125567.md) | [(10.6) d](/filings/0000950170-25-034820.md) | [(38.8)](/filings/0000950170-25-067081.md) | [0.4](/filings/0000950170-25-105106.md) | [(0.7)](/filings/0001193125-25-280270.md) | [(1.8) d](/filings/0001193125-26-104262.md) | [(0.9)](/filings/0001193125-26-224171.md) | [(0.8)](/filings/0001193125-26-344789.md) | [(1.0)](/filings/0001193125-25-280270.md) | [(1.3) d](/filings/0001193125-26-104262.md) | [(1.3)](/filings/0001193125-26-224171.md) | [(1.0)](/filings/0001193125-26-344789.md) |
| Interest expense | $m | [0.0](/filings/0000950170-23-061493.md) | [0.0 d](/filings/0000950170-24-033146.md) | [0.0](/filings/0000950170-24-059064.md) | [0.0](/filings/0000950170-24-093282.md) | [0.0](/filings/0000950170-24-125567.md) | [0.0 d](/filings/0000950170-25-034820.md) | not reported | not reported | not reported | not reported | not reported | not reported |
| Income tax | $m | [0.0](/filings/0000950170-24-125567.md) | [0.0 d](/filings/0000950170-25-034820.md) | not reported | [0.0](/filings/0000950170-25-105106.md) | [0.0](/filings/0001193125-25-280270.md) | [0.0 d](/filings/0001193125-26-104262.md) | not reported | [0.0](/filings/0000950170-25-105106.md) | [0.0](/filings/0001193125-25-280270.md) | [0.0 d](/filings/0001193125-26-104262.md) | not reported | not reported |
| Net income | $m | [(12.1)](/filings/0000950170-24-125567.md) | [(18.5) d](/filings/0000950170-25-034820.md) | [(25.6)](/filings/0000950170-25-067081.md) | [3.1](/filings/0000950170-25-105106.md) | [(0.1)](/filings/0001193125-25-280270.md) | [(0.7) d](/filings/0001193125-26-104262.md) | [0.3](/filings/0001193125-26-224171.md) | [(0.5)](/filings/0001193125-26-344789.md) | [(2.3)](/filings/0001193125-25-280270.md) | [1.5 d](/filings/0001193125-26-104262.md) | [0.7](/filings/0001193125-26-224171.md) | [(0.5)](/filings/0001193125-26-344789.md) |
| Diluted EPS | $ per share | [(2.57)](/filings/0000950170-24-125567.md) | not reported | [(2.11)](/filings/0000950170-25-067081.md) | [0.25](/filings/0000950170-25-105106.md) | [(0.01)](/filings/0001193125-25-280270.md) | not reported | [0.03](/filings/0001193125-26-224171.md) | [(0.04)](/filings/0001193125-26-344789.md) | [(0.19)](/filings/0001193125-25-280270.md) | not reported | [0.05](/filings/0001193125-26-224171.md) | [(0.04)](/filings/0001193125-26-344789.md) |
| Basic EPS | $ per share | [(2.57)](/filings/0000950170-24-125567.md) | not reported | [(2.11)](/filings/0000950170-25-067081.md) | [0.25](/filings/0000950170-25-105106.md) | [(0.01)](/filings/0001193125-25-280270.md) | not reported | [0.03](/filings/0001193125-26-224171.md) | [(0.04)](/filings/0001193125-26-344789.md) | [(0.19)](/filings/0001193125-25-280270.md) | not reported | [0.05](/filings/0001193125-26-224171.md) | [(0.04)](/filings/0001193125-26-344789.md) |

- Revenue: us-gaap:Revenues
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: us-gaap:InterestExpense, us-gaap:InterestExpenseNonoperating
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [24.5](/filings/0000950170-23-061493.md) | [24.0](/filings/0000950170-25-034820.md) | [24.8](/filings/0000950170-24-059064.md) | [20.0](/filings/0000950170-24-093282.md) | [19.4](/filings/0000950170-24-125567.md) | [18.9](/filings/0001193125-26-104262.md) | [17.3](/filings/0000950170-25-067081.md) | [17.0](/filings/0000950170-25-105106.md) | [15.6](/filings/0001193125-25-280270.md) | [14.7](/filings/0001193125-26-344789.md) | [14.1](/filings/0001193125-26-224171.md) | [13.2](/filings/0001193125-26-344789.md) |
| Current assets | $m | [37.8](/filings/0000950170-23-061493.md) | [49.9](/filings/0000950170-25-034820.md) | [34.9](/filings/0000950170-24-059064.md) | [21.6](/filings/0000950170-24-093282.md) | [20.7](/filings/0000950170-24-125567.md) | [19.8](/filings/0001193125-26-104262.md) | [17.9](/filings/0000950170-25-067081.md) | [17.3](/filings/0000950170-25-105106.md) | [16.5](/filings/0001193125-25-280270.md) | [15.4](/filings/0001193125-26-344789.md) | [14.6](/filings/0001193125-26-224171.md) | [13.4](/filings/0001193125-26-344789.md) |
| Total assets | $m | [66.3](/filings/0000950170-23-061493.md) | [75.6](/filings/0000950170-25-034820.md) | [36.1](/filings/0000950170-24-059064.md) | [21.6](/filings/0000950170-24-093282.md) | [20.8](/filings/0000950170-24-125567.md) | [19.8](/filings/0001193125-26-104262.md) | [18.0](/filings/0000950170-25-067081.md) | [17.4](/filings/0000950170-25-105106.md) | [16.6](/filings/0001193125-25-280270.md) | [15.4](/filings/0001193125-26-344789.md) | [14.6](/filings/0001193125-26-224171.md) | [13.5](/filings/0001193125-26-344789.md) |
| Current liabilities | $m | [9.1](/filings/0000950170-23-061493.md) | [30.3](/filings/0000950170-25-034820.md) | [14.9](/filings/0000950170-24-125567.md) | [8.5](/filings/0000950170-24-125567.md) | [7.6](/filings/0000950170-24-125567.md) | [7.1](/filings/0001193125-26-104262.md) | [4.9](/filings/0000950170-25-067081.md) | [4.8](/filings/0000950170-25-105106.md) | [6.2](/filings/0001193125-25-280270.md) | [3.6](/filings/0001193125-26-344789.md) | [2.1](/filings/0001193125-26-224171.md) | [1.5](/filings/0001193125-26-344789.md) |
| Total liabilities | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Shareholders' equity | $m | [43.4](/filings/0000950170-24-125567.md) | [32.8](/filings/0001193125-26-104262.md) | [9.4](/filings/0000950170-25-105106.md) | [13.1](/filings/0001193125-25-280270.md) | [13.1](/filings/0001193125-25-280270.md) | [12.8](/filings/0001193125-26-344789.md) | [13.1](/filings/0001193125-26-344789.md) | [12.6](/filings/0001193125-26-344789.md) | [10.3](/filings/0001193125-25-280270.md) | [11.9](/filings/0001193125-26-344789.md) | [12.6](/filings/0001193125-26-344789.md) | [12.0](/filings/0001193125-26-344789.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: not reported
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [(13.0) d](/filings/0000950170-24-125567.md) | [(5.5) d](/filings/0000950170-25-034820.md) | [(15.4)](/filings/0000950170-25-067081.md) | [(15.0) d](/filings/0000950170-25-105106.md) | [(0.6) d](/filings/0001193125-25-280270.md) | [(0.6) d](/filings/0001193125-26-104262.md) | [(1.6)](/filings/0001193125-26-224171.md) | [(0.4) d](/filings/0001193125-26-344789.md) | [(1.4) d](/filings/0001193125-25-280270.md) | [(0.9) d](/filings/0001193125-26-104262.md) | [(0.6)](/filings/0001193125-26-224171.md) | [(0.9) d](/filings/0001193125-26-344789.md) |
| Capital expenditure | $m | [0.0 d](/filings/0000950170-24-125567.md) | [0.0 d](/filings/0000950170-25-034820.md) | [0.4](/filings/0000950170-25-067081.md) | [(0.4) d](/filings/0000950170-25-105106.md) | [0.0 d](/filings/0001193125-25-280270.md) | [0.0 d](/filings/0001193125-26-104262.md) | [0.0](/filings/0000950170-25-067081.md) | [0.0 d](/filings/0000950170-25-105106.md) | [0.0 d](/filings/0001193125-25-280270.md) | [0.0 d](/filings/0001193125-26-104262.md) | not reported | not reported |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [4.8](/filings/0000950170-23-061493.md) | [4.6](/filings/0000950170-24-059064.md) | [4.7](/filings/0000950170-24-093282.md) | [4.7](/filings/0000950170-24-125567.md) | [12.1](/filings/0000950170-25-067081.md) | [12.4](/filings/0000950170-25-105106.md) | [12.2](/filings/0001193125-25-280270.md) | [12.4](/filings/0001193125-26-224171.md) | [12.3](/filings/0001193125-26-344789.md) | [12.3](/filings/0001193125-25-280270.md) | [12.4](/filings/0001193125-26-224171.md) | [12.4](/filings/0001193125-26-344789.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 12,248,950 at 2026-08-04, from the cover of the [10-Q filed 2026-08-11](/filings/0001193125-26-344789.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:42 ET. No prices; not investment advice.